Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | PTAFR | P25105 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102465 | 0.90 | ALDH1A1 (0.51) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL13101613 | 0.90 | ALDH1A1 (0.42) | ALDH1A1HTTGLSLMNAMEN1 | |
| SCHEMBL13102452 | 0.87 | ALDH1A1 (0.42) | ALDH1A1HTTGLSLMNAMEN1 | |
| SCHEMBL13102277 | 0.86 | ALDH1A1 (0.44) | CXCR3ALDH1A1HTTHDAC6LMNA | |
| SCHEMBL13102190 | 0.86 | CSNK1D (0.41) | ALDH1A1HTTGLSLMNAMEN1 | |
| SCHEMBL13102262 | 0.84 | CYP3A4 (0.42) | ALDH1A1HTTGLSLMNAMEN1 | |
| SCHEMBL3067313 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL13102227 | 0.84 | NPSR1 (0.41) | ALDH1A1HTTGLSLMNAMEN1 | |
| SCHEMBL13102195 | 0.82 | LMNA (0.44) | ALDH1A1LMNAMEN1KMT2ANPSR1 | |
| SCHEMBL13101676 | 0.81 | ALDH1A1 (0.42) | ALDH1A1HTTGLSLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | IDO1 1897/4885CXCR3 1932/4885ALDH1A1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.